TimesSquare Capital Management LLC Has $24.93 Million Stake in Vericel Co. (NASDAQ:VCEL)

TimesSquare Capital Management LLC raised its stake in Vericel Co. (NASDAQ:VCEL) by 54.8% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 590,145 shares of the biotechnology company’s stock after buying an additional 209,009 shares during the quarter. TimesSquare Capital Management LLC’s holdings in Vericel were worth $24,934,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of the stock. International Assets Investment Management LLC lifted its stake in Vericel by 4,126.7% during the 3rd quarter. International Assets Investment Management LLC now owns 634 shares of the biotechnology company’s stock valued at $27,000 after acquiring an additional 619 shares in the last quarter. CWM LLC raised its holdings in shares of Vericel by 319.0% in the second quarter. CWM LLC now owns 662 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 504 shares during the last quarter. Farther Finance Advisors LLC lifted its position in shares of Vericel by 48.1% during the third quarter. Farther Finance Advisors LLC now owns 1,247 shares of the biotechnology company’s stock valued at $53,000 after purchasing an additional 405 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Vericel by 22.2% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,773 shares of the biotechnology company’s stock worth $77,000 after purchasing an additional 322 shares during the last quarter. Finally, Nisa Investment Advisors LLC grew its position in Vericel by 9.7% in the 2nd quarter. Nisa Investment Advisors LLC now owns 2,484 shares of the biotechnology company’s stock worth $114,000 after purchasing an additional 220 shares in the last quarter.

Analysts Set New Price Targets

Several equities analysts have commented on the stock. StockNews.com raised shares of Vericel from a “sell” rating to a “hold” rating in a research report on Friday. BTIG Research dropped their price target on Vericel from $56.00 to $55.00 and set a “buy” rating on the stock in a report on Monday, July 15th. TD Cowen boosted their price objective on Vericel from $55.00 to $60.00 and gave the stock a “buy” rating in a research report on Tuesday, August 27th. Canaccord Genuity Group began coverage on Vericel in a research report on Friday, August 9th. They set a “buy” rating and a $57.00 target price for the company. Finally, Stephens lifted their target price on Vericel from $56.00 to $58.00 and gave the stock an “overweight” rating in a research note on Friday, August 2nd. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat.com, Vericel currently has an average rating of “Moderate Buy” and a consensus price target of $57.71.

Vericel Price Performance

Shares of VCEL opened at $54.00 on Monday. The firm has a market cap of $2.65 billion, a PE ratio of -5,400,000.00 and a beta of 1.66. Vericel Co. has a 1 year low of $32.28 and a 1 year high of $54.47. The stock’s fifty day moving average price is $44.27 and its two-hundred day moving average price is $46.40.

Vericel (NASDAQ:VCEL) last released its quarterly earnings data on Thursday, November 7th. The biotechnology company reported ($0.02) EPS for the quarter, beating the consensus estimate of ($0.05) by $0.03. The business had revenue of $57.91 million for the quarter, compared to the consensus estimate of $55.32 million. Vericel had a net margin of 0.37% and a return on equity of 0.35%. Sell-side analysts anticipate that Vericel Co. will post 0.12 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director Steven C. Gilman sold 5,833 shares of the business’s stock in a transaction on Wednesday, October 2nd. The stock was sold at an average price of $40.35, for a total transaction of $235,361.55. Following the sale, the director now directly owns 11,000 shares in the company, valued at approximately $443,850. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In related news, CEO Dominick Colangelo sold 17,500 shares of the business’s stock in a transaction dated Wednesday, October 16th. The stock was sold at an average price of $41.38, for a total transaction of $724,150.00. Following the completion of the transaction, the chief executive officer now directly owns 220,937 shares in the company, valued at $9,142,373.06. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Steven C. Gilman sold 5,833 shares of the firm’s stock in a transaction dated Wednesday, October 2nd. The shares were sold at an average price of $40.35, for a total value of $235,361.55. Following the completion of the sale, the director now directly owns 11,000 shares in the company, valued at approximately $443,850. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 29,166 shares of company stock valued at $1,200,764. Company insiders own 5.20% of the company’s stock.

Vericel Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.